Page 3 - Robert Iannone News Today

/PRNewswire/ -- Stand Up To Cancer® (SU2C) and Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announce a three-year, $4 million research collaboration to...

Jazz shares results from sleep medicine research and the development of novel therapeutic options for people living with sleep disorders DUBLIN, June 9, 2021 /PRNewswire/ -- Jazz Pharmaceuticals

DUBLIN, June 9, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc today announced that 13 abstracts sponsored by Jazz Pharmaceuticals and five abstracts from investigator-sponsored trials will be... | June 9, 2021

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 13 abstracts sponsored by Jazz Pharmaceuticals and five abstracts from...

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it and its investigator sponsors will present four new abstracts at the virtual...

Jazz Pharmaceuticals Announces First Quarter 2021 Financial Results Continued Zepzelca Growth Across Second-Line SCLC Setting Xywav in Idiopathic Hypersomnia Granted FDA Priority Review and an August 12, 2021, PDUFA Target Action Date On Track to Close Acquisition of GW Pharmaceuticals plc in Early May, Creating an Innovative, High-Growth, Global Biopharma Leader Secured $5.35 Billion Financing Including $1.5 Billion Senior Secured Notes in Connection with GW Acquisition 23% of Revenue from Rec...

(0) Xywav demonstrated statistically significant differences in change in Epworth Sleepiness Scale score (p-value The safety profile in this study was consistent with the known safety profile of Xywav with no new safety signals observed in this population Company to host investor webcast today at 12:30 p.m. ET DUBLIN, April 20, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive results from the Phase 3 study of Xywav TM (calcium, magnesium, potassium, and so...

Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2020 Financial Results DUBLIN, Feb. 23, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2020 and provided financial guidance for 2021. "In 2020, we made meaningful progress toward our goal to significantly grow and diversify 2022 revenues from products launched since 2019, highlighted by the strong execution of our U.S. launches of both Zepzelca and ...

(2) DUBLIN, Feb. 16, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the completion of the rolling submission for the supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of adult patients with idiopathic hypersomnia. If approved, Xywav will be the first and only approved treatment in the U.S. for adults with i...

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the completion of the rolling submission for the supplemental New Drug Application...